As of 2025-11-17, the Intrinsic Value of Affluent Medical SAS (AFME.PA) is (11.67) EUR. This AFME.PA valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 1.58 EUR, the upside of Affluent Medical SAS is -838.80%.
The range of the Intrinsic Value is (32.50) - (7.44) EUR
Based on its market price of 1.58 EUR and our intrinsic valuation, Affluent Medical SAS (AFME.PA) is overvalued by 838.80%.
Note: result may not be accurate due to the invalid valuation result of DCF model.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | (32.50) - (7.44) | (11.67) | -838.8% |
| DCF (Growth 10y) | (7.97) - (32.22) | (12.10) | -865.9% |
| DCF (EBITDA 5y) | (2.61) - (3.11) | (1,234.50) | -123450.0% |
| DCF (EBITDA 10y) | (3.96) - (4.76) | (1,234.50) | -123450.0% |
| Fair Value | -1.87 - -1.87 | -1.87 | -218.56% |
| P/E | (3.88) - (2.29) | (3.25) | -305.7% |
| EV/EBITDA | (0.78) - (0.95) | (0.87) | -154.8% |
| EPV | (1.38) - (1.78) | (1.58) | -200.0% |
| DDM - Stable | (4.01) - (23.50) | (13.76) | -970.7% |
| DDM - Multi | (4.67) - (21.72) | (7.74) | -589.6% |
| Market Cap (mil) | 62.17 |
| Beta | 0.35 |
| Outstanding shares (mil) | 39.35 |
| Enterprise Value (mil) | 78.20 |
| Market risk premium | 5.82% |
| Cost of Equity | 7.99% |
| Cost of Debt | 5.00% |
| WACC | 7.40% |